The report discusses the FDA's approval of Keytruda for second-line PD-L1+ lung cancer patients and its implications for the market. It highlights the expected uptake of Keytruda, the competitive landscape with Opdivo, and future expectations for label expansion. The report also covers Merck's diverse portfolio and upcoming catalysts.
documents/EFTA00598930.pdf
{}